US2008261907A1PendingUtilityA1

Compositions and methods of sphingosine kinase inhibitors in radiation therapy of various cancers

53
Assignee: UNIV SOUTHERN CALIFORNIAPriority: Nov 30, 2006Filed: Nov 30, 2007Published: Oct 23, 2008
Est. expiryNov 30, 2026(~0.3 yrs left)· nominal 20-yr term from priority
Inventors:Uttam K. SinhaRizwan Masood
A61P 31/00A61P 35/00C12N 2310/14C12Y 207/01091C12N 15/1137
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to Sphingosine kinase inhibitors that are useful for treating various cancers. The invention further relates to compositions and methods of SPK inhibitors, including siRNAs, which specifically block gene expression of SPK and potentiates the effect of radiation in the treatment of various cancers.

Claims

exact text as granted — not AI-modified
1 . A composition comprising an inhibitor that specifically blocks the expression of sphingosine kinase and potentiates the effect of radiation in more than one type of cancer cell, wherein said cancer cell is a breast, prostate, colorectal, lung, bladder, head and neck, intestine, ovarian, skin or the like. 
     
     
         2 . The composition according to  claim 1 , wherein said cancer cell is in a mammal. 
     
     
         3 . The composition according to  claim 1 , wherein said inhibitor is siRNA. 
     
     
         4 . The composition according to  claim 3 , wherein said siRNA comprises 19-25 oligonucleotides. 
     
     
         5 . The composition according to  claim 4 , wherein said siRNA is double stranded and comprises the sense sequence of SEQ ID NO: 1 and antisense sequence of SEQ ID NO: 2. 
     
     
         6 . The composition according to  claim 5 , wherein said sense sequence is SEQ ID NO: 3 and antisense sequence is SEQ ID NO: 4. 
     
     
         7 . A therapeutic agent comprising a composition of an inhibitor, that specifically blocks the expression of sphingosine kinase and potentiates the effect of radiation in more than one type of cancer cell, wherein said cancer cell is a breast, prostate, colorectal, lung, bladder, head and neck, intestine, ovarian, skin or the like. 
     
     
         8 . The therapeutic agent according to  claim 7 , wherein said cancer cell is in a mammal. 
     
     
         9 . The therapeutic agent according to  claim 7  wherein said inhibitor is siRNA. 
     
     
         10 . The therapeutic agent according to  claim 9 , wherein said siRNA comprises 19-25 oligonucleotides. 
     
     
         11 . The therapeutic agent according to  claim 10 , wherein said siRNA is double stranded and comprises the sense sequence of SEQ ID NO: 1 and antisense sequence of SEQ ID NO: 2. 
     
     
         12 . The therapeutic agent according to  claim 10 , wherein the sense sequence is SEQ ID NO: 3 and antisense sequence is SEQ ID NO: 4. 
     
     
         13 . A composition comprising an inhibitor that specifically blocks the expression of sphingosine kinase and potentiates the effect of radiation in any cancer cell. 
     
     
         14 . The composition according to  claim 13 , wherein said inhibitor is siRNA. 
     
     
         15 . The composition according to  claim 14 , wherein said siRNA comprises 19-25 oligonucleotides. 
     
     
         16 . The composition according to  claim 14 , wherein said siRNA is double stranded and comprises the sense sequence of SEQ ID NO: 1 and antisense sequence of SEQ ID NO: 2. 
     
     
         17 . The composition according to  claim 14 , wherein said siRNA is double stranded and comprises the sense sequence of SEQ ID NO: 3 and antisense sequence of SEQ ID NO: 4. 
     
     
         18 . A therapeutic agent comprising a composition comprising an inhibitor that specifically blocks the expression of sphingosine kinase and potentiates the effect of radiation in any cancer cell. 
     
     
         19 . The therapeutic agent according to  claim 18 , wherein said inhibitor is siRNA. 
     
     
         20 . The therapeutic agent according to  claim 19 , wherein said siRNA comprises 19-25 oligonucleotides. 
     
     
         21 . The therapeutic agent according to  claim 19 , wherein said siRNA is double stranded and comprises the sense sequence of SEQ ID NO: 1 and antisense sequence of SEQ ID NO: 2. 
     
     
         22 . A therapeutic agent according to  claim 19 , wherein said siRNA is double stranded and comprises the sense sequence of SEQ ID NO: 3 and antisense sequence of SEQ ID NO: 4.

Join the waitlist — get patent alerts

Track US2008261907A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.